Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Correspondence

Correspondence to editorial on “Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C”

Tom Ryu, Young Chang, Seung Up Kim, Jae Young Jang

Clin Mol Hepatol. 2025;31(2):e203-e205. Published online February 24, 2025

DOI: https://doi.org/10.3350/cmh.2025.0179

View: 626 Download: 19 Web of Science: 1 Crossref: 1

Age serves as the silent architect of FIB-4’s precision in unveiling advanced hepatic fibrosis in MASLD with T2DM: Correspondence to letter to the editor on “Diagnostic accuracy of the fibrosis-4 index for advanced liver fibrosis in nonalcoholic fatty liver disease with type 2 diabetes: a systematic review and meta-analysis”

Ji Won Han, Dae Won Jun

Clin Mol Hepatol. 2025;31(2):e152-e154. Published online December 30, 2024

DOI: https://doi.org/10.3350/cmh.2024.1160

View: 1060 Download: 31

Original Article

Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C

Tom Ryu, Young Chang, Soung Won Jeong, Jeong-Ju Yoo, Sae Hwan Lee, Sang Gyune Kim, Young Seok Kim, Hong Soo Kim, Seung Up Kim, Jae Young Jang

Clin Mol Hepatol. 2025;31(2):548-562. Published online January 9, 2025

DOI: https://doi.org/10.3350/cmh.2024.0904

View: 1551 Download: 111 Web of Science: 4 Crossref: 1

Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation

Soon Kyu Lee, Ho Joong Choi, Young Kyoung You, Pil Soo Sung, Seung Kew Yoon, Jeong Won Jang, Jong Young Choi

Clin Mol Hepatol. 2025;31(1):131-146. Published online October 2, 2024

DOI: https://doi.org/10.3350/cmh.2024.0451

View: 1955 Download: 192 Web of Science: 4 Crossref: 2

Review

Screening strategy for non-alcoholic fatty liver disease

Saisai Zhang, Lung-Yi Mak, Man-Fung Yuen, Wai-Kay Seto

Clin Mol Hepatol. 2023;29(Suppl):S103-S122. Published online November 30, 2022

DOI: https://doi.org/10.3350/cmh.2022.0336

View: 7002 Download: 277 Web of Science: 24 Crossref: 22

Risk factors in nonalcoholic fatty liver disease

Eunji Ko, Eileen L. Yoon, Dae Won Jun

Clin Mol Hepatol. 2023;29(Suppl):S79-S85. Published online December 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0398

View: 6869 Download: 273 Web of Science: 43 Crossref: 48

Original Article

Prognostic role of computed tomography analysis using deep learning algorithm in patients with chronic hepatitis B viral infection

Jeongin Yoo, Heejin Cho, Dong Ho Lee, Eun Ju Cho, Ijin Joo, Sun Kyung Jeon

Clin Mol Hepatol. 2023;29(4):1029-1042. Published online August 29, 2023

DOI: https://doi.org/10.3350/cmh.2023.0190

View: 4661 Download: 176 Web of Science: 6 Crossref: 5

Editorial

Implications of comorbidities in nonalcoholic fatty liver disease

Sherlot Juan Song, Vincent Wai-Sun Wong

Clin Mol Hepatol. 2023;29(2):384-389. Published online March 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0066

View: 5147 Download: 100 Web of Science: 2 Crossref: 2

Review

Development and prognosis of hepatocellular carcinoma in patients with diabetes

Takuma Nakatsuka, Ryosuke Tateishi

Clin Mol Hepatol. 2023;29(1):51-64. Published online July 29, 2022

DOI: https://doi.org/10.3350/cmh.2022.0095

View: 7416 Download: 270 Web of Science: 38 Crossref: 40

Impact of diabetes, obesity, and dyslipidemia on the risk of hepatocellular carcinoma in patients with chronic liver diseases

Hwang Sik Shin, Baek Gyu Jun, Sang-Wook Yi

Clin Mol Hepatol. 2022;28(4):773-789. Published online August 8, 2022

DOI: https://doi.org/10.3350/cmh.2021.0383

View: 7042 Download: 266 Web of Science: 42 Crossref: 46

Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review

Lei Miao, Jing Xu, Giovanni Targher, Christopher D Byrne, Ming-Hua Zheng

Clin Mol Hepatol. 2022;28(4):725-738. Published online March 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0015

View: 6463 Download: 266 Web of Science: 15 Crossref: 18

Original Article

The effect of diabetes and prediabetes on the prevalence, complications and mortality in nonalcoholic fatty liver disease

Cheng Han Ng, Kai En Chan, Yip Han Chin, Rebecca Wenling Zeng, Pei Chen Tsai, Wen Hui Lim, Darren Jun Hao Tan, Chin Meng Khoo, Lay Hoon Goh, Zheng Jye Ling, Anand Kulkarni, Lung-Yi Loey Mak, Daniel Q Huang, Mark Chan, Nicholas WS Chew, Mohammad Shadab Siddiqui, Arun J. Sanyal, Mark Muthiah

Clin Mol Hepatol. 2022;28(3):565-574. Published online May 19, 2022

DOI: https://doi.org/10.3350/cmh.2022.0096

View: 9965 Download: 226 Web of Science: 63 Crossref: 64

Systematic review with meta-analysis: Non-alcoholic fatty liver disease and the association with pregnancy outcomes

Hydar El Jamaly, Guy D Eslick, Martin Weltman

Clin Mol Hepatol. 2022;28(1):52-66. Published online September 17, 2021

DOI: https://doi.org/10.3350/cmh.2021.0205

View: 9306 Download: 251 Web of Science: 18 Crossref: 24

Review

From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?

Seong Hee Kang, Yuri Cho, Soung Won Jeong, Seung Up Kim, Jin-Woo Lee, On behalf of Korean NAFLD Study Group

Clin Mol Hepatol. 2021;27(2):257-269. Published online March 22, 2021

DOI: https://doi.org/10.3350/cmh.2021.0067

View: 10585 Download: 449 Web of Science: 71 Crossref: 74

Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease

Kyung-Soo Kim, Byung-Wan Lee

Clin Mol Hepatol. 2020;26(4):430-443. Published online August 14, 2020

DOI: https://doi.org/10.3350/cmh.2020.0137

View: 11889 Download: 505 Web of Science: 46 Crossref: 48

Original Article

Effects of different exercise modalities on novel hepatic steatosis indices in overweight women with type 2 diabetes

Ebrahim Banitalebi, Mohammad Faramarzi, Samira Nasiri, Majid Mardaniyan, Vahid Rabiee

Clin Mol Hepatol. 2019;25(3):294-304. Published online May 30, 2019

DOI: https://doi.org/10.3350/cmh.2018.0086

View: 8692 Download: 279 Web of Science: 15 Crossref: 19

Case Report

Three cases of glycogenic hepatopathy mimicking acute and relapsing hepatitis in type I diabetes mellitus

Jae Hwang Cha, Sang Ho Ra, Yu Mi Park, Yong Kwan Ji, Ji Hyun Lee, So Yeon Park, Soon Koo Baik, Sang Ok Kwon, Mee Yon Cho, Moon Young Kim

Clin Mol Hepatol. 2013;19(4):421-425. Published online December 28, 2013

DOI: https://doi.org/10.3350/cmh.2013.19.4.421

View: 9172 Download: 83 Crossref: 25

4

Occurrence of diabetic ketoacidosis and autoimmune thyroiditis in a patient treated with pegylated interferon-alpha 2b and ribavirin for chronic hepatitis C

Yun Nah Lee, M.D., Soung Won Jeong, M.D., Jae Hee Lim, M.D., Yang Seon Ryu, M.D., Seong Ran Jeon, M.D., Sang Kyun Kim, M.D., Jae Young Jang, M.D., Young Seok Kim, M.D., Boo Sung Kim, M.D., Mi Oh Roh, M.D.

Clin Mol Hepatol. 2010;16(2):187-191. Published online June 25, 2010

DOI: https://doi.org/10.3350/kjhep.2010.16.2.187

View: 6522 Download: 32 Crossref: 1

3

Clinical features of gas-forming Liver abscesses: comparison between diabetic and nondiabetic patients

Chang Jae Lee, M.D., Sang Young Han, M.D., Sung Wook Lee, M.D., Yang Hyun Baek, M.D., Seok Reyol Choi, M.D., Myung Hwan Roh, M.D., Jong Hoon Lee, M.D., Jin Seok Jang, M.D., Jin Han, M.D., Su Hyun Cho, M.D., Se Woong Choi, M.D.

Clin Mol Hepatol. 2010;16(2):131-138. Published online June 25, 2010

DOI: https://doi.org/10.3350/kjhep.2010.16.2.131

View: 5708 Download: 77 Crossref: 11

Differential Diagnosis of Diabetes Mellitus caused by Liver Cirrhosis and Other Type 2 Diabetes Mellitus

Min Geun Kim , Won Choong Choi

Clin Mol Hepatol. 2006;12(4):524-529. Published online January 1, 1970

View: 4627 Download: 129

Prevalence and Clinical Significance of Diabetes Mellitus in Patients with Liver Cirrhosis

Kwon So Yeong

Clin Mol Hepatol. 2003;9(3):205-211. Published online January 1, 1970

View: 3204 Download: 29

1 |

Viewed By 12185	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 7614	MAFLD: How is it different from NAFLD?
Viewed By 6635	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 5876	Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment
Viewed By 5481	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 355	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 338	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 223	MAFLD: How is it different from NAFLD?
Cited By 114	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 110	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Search